Nationwide Children’s Hospital in Columbus, Ohio has announced the creation of Andelyn Biosciences, a for-profit subsidiary company that will ultimately manufacture commercial-scale gene therapy products.
Andelyn will launch this summer and operate out of the Abigail Wexner Research Institute, which is already known as a leader in developing gene therapies. The new company will start by producing gene therapy components for pharma companies running clinical trials.
Nationwide Children’s is in the process of securing a permanent location for Andelyn, which they hope to select in the next couple of months, so that they can start construction by the end of the year and open the facility in 2023. This will enable Andelyn to contract with drugmakers to make commercial products.
Read the Columbus Dispatch article
